G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and relaxing because that relentless routine of meetings, deadlines, and what-not has returned. You knew this would happen, yes? As always, we are coping by quaffing multiple cups of stimulation — alternating between Cinnamon Dolce and Southern Pecan, if you care — and invite you to join us. Remember, no prescription is required. Meanwhile, here are some tidbits to help you along. Hope you have a terrifically productive day and do keep in touch …

GlaxoSmithKline may pay $10 billion to expand its consumer health care business by purchasing the 36.5 percent stake that Novartis holds in its Consumer Healthcare unit, The Sunday Times tells us. The joint venture was set up in April 2014 as part of a larger asset swap between the two companies. Novartis has an option to sell the stake back to Glaxo, which comes into force next March. And Novartis could use the proceeds to finance a large takeover.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.